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The context of a diagnostic test is a critical component for the interpretation of its result. This context defines the
pretest probability of the diagnosis and forms the basis for the interpretation and value of adding the diagnostic
test. In the field of acute kidney injury, a multitude of early diagnostic biomarkers have been developed, but
utilization in the appropriate context is less well understood and has not been codified until recently. In order to
better operationalize the context and pretest probability assessment for acute kidney injury diagnosis, the renal angina
concept was proposed in 2010 for use in both children and adults. Renal angina has been assessed in approximately
1,000 subjects. However, renal angina as a concept is still unfamiliar to most clinicians and the rationale for introducing
the term is not obvious. We therefore review the concept and development of renal angina, and the currently available
data validating it. We discuss the various arguments for and against this construct. Future research testing the
performance of renal angina with acute kidney injury biomarkers is warranted.Introduction
The use of advanced diagnostics (that is, beyond history
and physical examination) forms a cornerstone of modern
medicine. For any given diagnostic test, the context of that
test is a critical component for the interpretation of the
results. This context is referred to as pretest probability and
forms the basis for the interpretation of any diagnostic test.
For instance, if a young healthy pregnant woman presented
for a medical examination and had a very elevated prostate
specific antigen value, the patient’s physician can safely
dismiss this as a specious result. However, if the patient was
a 70-year-old man with nocturia with the same elevated
prostate specific antigen value, the clinician would arrive at
a different conclusion. While this is an extreme example, it
demonstrates the simple rule that all clinicians follow: the
value of any diagnostic study without clinical context is
minimized. The assessment of pretest probability for any
diagnosis is informed by all of the core aspects of a medical* Correspondence: minkchawla@gmail.com
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unless otherwise stated.examination (that is, history, physical examination, and all
available medical information). The integration of these
data then informs a differential diagnosis that guides the
selection and interpretation of diagnostic studies.
In the past 30 years, protein biomarkers have become
important sources for development of diagnostic tests.
The biomarker that many hold up as a gold standard for
comparison is troponin for the diagnosis of acute coronary
syndrome (ACS) and myocardial infarction. The use,
accuracy, and utilization of troponin are well appreciated
and have been reviewed extensively [1]. The typical
utilization for troponin and other ACS biomarkers is in
the setting of patients who present with angina pectoris
and angina pectoris-type symptoms (for example, chest
pain, dyspnea, referred visceral pain). When used in this
venue, troponin serves as an outstanding biomarker,
which helps to either rule in or rule out significant ACS.
This performance is due to two facts: troponin is a good
biomarker with a high sensitivity and specificity; and the
pretest probability of a patient with angina to have ACS is
high. However, when troponin is utilized in a less selective
fashion, in patients who have a lower pretest probability of
ACS, the performance of this much heralded biomarker
deteriorates [2,3]. For example, the sensitivity and specificity. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Acute kidney injury risk factors
Adults Children
Susceptibilities Advanced age Very premature neonates
Congestive heart failure Heart failure
Hypertension Stem cell transplant
Diabetes mellitus
Chronic kidney disease
Exposures Volume depletion Volume depletion
Cardiopulmonary bypass Cardiopulmonary bypass
Nephrotoxin exposure Nephrotoxin exposure
Mechanical ventilation Mechanical ventilation
Sepsis Sepsis
Vasopressors Vasopressors
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pectoris are 88% and 88%, respectively [4]. When this
same assay was used in critically ill patients without
typical anginal symptoms, only one-half of the patients
with an elevated troponin were found to have any type of
ACS [3]. In this study, the false positive elevations were
attributed to other causes (that is, sepsis, renal failure).
Studies such as these demonstrate that for any biomarker,
even one as good as troponin, clinical context and pretest
probability assessment remain paramount.
Angina
Deconstructing angina pectoris
The differential diagnosis for chest pain is taught to all
medical students early on in their medical education.
The concept of chest pain and its character (sharp
versus squeezing), onset (sudden versus gradual), and
location (substernal) are imparted to trainees. These
signs and symptoms are then placed into context with
the well-known risk factors of ACS (family history,
diabetes, hypertension, elevated cholesterol, and so forth).
With these data in hand, a clinician is able to develop a
level of suspicion for the presence or absence of ACS. This
clinical approach has been instrumental in the evaluation
of patients with ACS, and has been further improved with
the appropriate use of sensitive and specific biomarkers
(for example, troponins and before that creatinine kinase).
As detailed above, the approach to a patient with
suspicion for ACS has been well constructed and validated,
but the same is not true for patients with acute kidney
injury (AKI). Only recently has AKI developed a consensus
definition and there remains a tendency to diagnose the
disease late in its course [5,6]. To improve the time to
diagnosis, multiple AKI biomarkers have been discovered,
assessed, and validated. These biomarkers have been tested
in scores of studies and found to be good diagnostic
markers [7-10]. However, many of these biomarkers failed
to achieve troponin-like performance. For purposes of
comparison, most diagnostic tests can be assessed using a
receiver operating characteristic (ROC) assessment. The
range for this test is an area under the curve (AUC) of 0.50
to 1.00. At a ROC AUC value of 0.50, the test has
maximum uncertainty and is equivalent of flipping a
coin. At a ROC AUC value of 1.00, the test performs
with perfect diagnostic capacity. The fourth-generation
troponin assays have a ROC AUC performance of 0.89 to
0.91 in patients with angina pectoris, which is excellent
[4]. In most cases, many of the current AKI biomarkers
typically have a performance in the range of 0.65 to 0.84
when tested using current study designs [8-11].
However, ROC curves are influenced by the severity of
illness found in the population under study. We considered
that some of the underperformance was in part not due to
poor biomarkers, but rather due to inadequate assessmentof context and pretest probability. In fact, most of these
studies wherein the AKI biomarkers performed poorly
were in patient cohorts with heterogeneous disease
processes, while the performance of AKI biomarkers was
much better in more homogeneous populations (for
example, postoperative cardiac surgery in children) [8-10].
As shown earlier, the performance of troponin drops
substantially when used in heterogeneous populations. We
thus developed and proposed the concept of renal angina
(RA) in order to better assess pretest probability of AKI to
inform the use and interpretation of AKI biomarkers [12].
Constructing renal angina
With this goal in mind, we analyzed the two core
components of angina pectoris – risk factors plus
symptomology – to develop the parallel of RA. The
risk factors for AKI are well documented in various
patient populations (Table 1) [5,12], but AKI does not
have any visceral symptoms. Put another way, AKI
does not hurt. We therefore could not use flank pain
or dysuria to develop the symptomology of AKI. Instead,
we utilized the clinical signs that are used to assess AKI:
urine output, changes in serum creatinine, and percent
fluid overload. We hypothesized that very small changes
in serum creatinine, short periods of oliguria, and fluid
overload could be used in place of visceral anginal
symptoms. We then used combinations of risk factors
and modest changes in serum creatinine, urine output,
and fluid overload to develop the definition of RA.
The premise of this approach is as follows. Patients
who have many risk factors for ACS do not need to
show much chest pain in order for a clinician to become
suspicious that ACS is present. An example would be an
obese diabetic male with mild heartburn symptoms. The
same symptomology in an Olympic athlete in her prime
would engender less suspicion of ACS with the same
level of syptomology. Inherent in the angina pectoris
approach is the notion that the presence of multiple
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suspicion of ACS. We thus developed three hazard
tranches (HT) to incorporate this operating concept into
RA (Figure 1). In our proposal, each HT has equivalent
net risk for the development of AKI. HT1 has multiple
AKI risk factors and requires few signs to achieve the
RA threshold. HT2 is comprised of patients with some
AKI risk factors and thus requires slightly more signs to
achieve the RA threshold. HT3 includes patients with few
risk factors for AKI and thus requires more definitive
signs to achieve the RA threshold.
The inherent hypothesis in this approach is that HT1,
HT2, and HT3 would have similar risk profiles for the
development of severe AKI, defined by Kidney Disease:
Improving Global Outcomes stages II to III. We proposed
criteria for both children and adults [12]. The second
hypothesis of RA is that, like angina pectoris, it should be
very sensitive and have a high negative predictive value
(NPV). The third hypothesis of RA is that when AKI
biomarkers are used in patients with RA, the diagnostic
performance of those biomarkers will improve, similar to
troponin use in angina pectoris.
Renal angina risk prediction
Since the initial RA proposal in 2010, RA has been
assessed in four pediatric cohorts and one adult cohort
[13]. In the pediatric cohorts, a renal angina index (RAI)
was developed and validated to operationalize the
bedside use of RA (Figure 2). In a recent study, Basu
and colleagues assessed four cohorts of critically ill
pediatric patients and assessed the performance of RA using
the RAI [13]. They found that RA could be operationalized
for use in the pediatric ICU population to predict severe
AKI 3 days after ICU admission. The performance of the
RAI in each of these pediatric cohorts was remarkablyFigure 1 Hazard tranches to incorporate an operating concept
into reginal angina. Each hazard tranche (HT) has equivalent net risk
for the development of acute kidney injury (AKI). RA, reginal angina.consistent with a risk prediction performance of ROC AUC
of 0.74 to 0.81 (Table 2) and a NPV of 92 to 99%.
RA has been assessed in one large cohort of critically
ill adult patients. In a study of over 500 adult ICU
patients in Italy, Cruz and colleagues assessed the
capacity of RA to predict severe AKI [14]. Their results
are consistent with the performance of RA in children.
The authors found that RA was strongly associated with
the development of AKI, and that the sensitivity was
high (92%) with a high NPV (99%) (Table 3). In both the
adult and pediatric cohorts, the NPV was high (92 to 99%)
(Table 3). In addition, Cruz and colleagues assessed the
performance of each of the HTs [14]. They found the
performance to indicate that the HTs perform similarly,
and the sensitivity is high with an excellent NPV.
Overall, the preliminary studies of RA endorse the
notion that this approach can be operationalized at the
bedside. Moreover, the intertranche consistency and the
consistent finding of a high NPV suggest that absence of
RA can be used to rule out AKI. In addition, the fact
that the pediatric and adult cohorts perform similarly
offers further evidence of the pediatric Risk, Injury,
Failure, Loss, End-staging system being well calibrated
to the adult Risk, Injury, Failure, Loss, End-staging AKI
criteria, and that this pretest probability approach is
relevant in AKI to both adults and children. Since the
disease epidemiology leading to AKI is similar in children
and adults (sepsis, post-bypass, nephrotoxic medication
injury) and AKI is independently associated with increased
mortality in children and adults, it is in fact not surprising
that the RA construct and AKI definitions yield similar
results. Most novel AKI biomarkers have been tested
initially in children, since they provide a clinical cohort
less confounded by chronic disease. We support the
recent recommendation from the American Society of
Nephrology Acute Kidney Injury Advisory Committee to
include adolescents in adult AKI [15].
The case against renal angina
Of course, like any new paradigm, there are sensible
arguments against introducing the term and the concept
of RA. First and foremost, the term angina is most
commonly associated with angina pectoris and many
clinicians will associate it with ischemia. However, the
term is not specific to the heart or to ischemia. Various
forms of angina have been described, notably Ludwig’s
angina and Vincent’s angina. Wilhelm Friedrich von
Ludwig first described Ludwig’s angina in 1836, which is
an infection in the floor of the mouth. According to
Merriam-Webster, the term Vincent’s angina was first
used in 1903 and was often used interchangeably with the
term trench mouth. Neither Ludwig’s angina nor Vincent’s
angina is associated with chest pain, arterial stenosis, or
ischemia per se [16-19]. Both of these forms of angina are
Figure 2 Renal angina index for children. The renal angina index establishes point values for both risk tranche and injury threshold to use in
computing a composite score. The integer values assigned for each risk tranche (that is, 1, 3, 5) are derived directly by comparing cohorts
extracted from established pediatric acute kidney injury (AKI) data in an epidemiologic study. The integer values given for injury are denoted as
two-exponent to signify doubling of injury for incremental increases in creatinine or fluid overload on admission. The computed index ranges from 1
to 40. Through sensitivity analyses, cutoff value ≥8 has been established as fulfillment of renal angina. eCrCl, estimated creatinine clearance; FO, fluid
output; OR, odds ratio; PICU, pediatric ICU; ppCRRT, positive-pressure continuous renal replacement therapy. Adapted with permission from [13].
Chawla et al. Critical Care  (2015) 19:93 Page 4 of 5still currently used in the medical literature [18-20]. The
notion that angina is only associated with the current
cardiac vernacular is thus not supported by its historical
and current use.
Second, even if the term angina can be placed into the
above context it may be unfamiliar to many clinicians.
However, this is already changing – the term RA is now
well established in the literature. The original paper
published in 2010 [12] has been cited over 50 times
[7,13,21-37] (edited bibliography). In addition, validation
of the pediatric RAI has been published in Kidney
International [13] and validation of the adult RA proposal
was published recently in Clinical Journal of the American
Society of Nephrology [14].
Third, it is well known that AKI occurs most commonly
in the critically ill, and often in this population as part of
multiple organ failure. Such patients already have the AKI
equivalent of chest pain. However, AKI is still common inTable 2 Diagnostic performance of renal angina
Peds1 Peds2 Peds3 Peds4 Adults [14]
n 144 118 108 214 506
Sensitivity (%) 75 58 91 93 92
Specificity (%) 73 90 71 36 62
Positive predictive
value (%)
40 39 26 18 16
Negative predictive
value (%)
92 95 99 97 99
ROC AUCa 0.77 0.74 0.81 0.80 n/a
Pediatric cohorts as reported by Basu and colleagues [13]. n/a, not available.
aReceiver operator characteristics area under the curve (ROC AUC) for the
renal angina index.patients without such severity of illness, and in fact these
low-risk patients exhibit a larger relative hazard when they
develop AKI [38]. Patients outside the ICU are similarly
low risk and yet the importance of identifying AKI in this
population is not in question. Indeed, the purpose of RA
is to provide a framework for risk stratification that
incorporates static and dynamic factors so the clinician
can make sensible decisions regarding risk stratification.
Conclusions
The concept of RA to operationalize pretest probability
assessment in AKI appears to have good performance
metrics. Importantly, in children the combination of RA
and AKI biomarkers has excellent diagnostic performance
and this combination strategy should be the primary focus
of RA utilization. Future research will need to assess the
performance of RA with AKI biomarkers in adults. In
addition, it is important to recognize that RA will need to
be adjusted and recalibrated as new information becomes
available. New diseases and nephrotoxins will evolve over
the years and other important risk factors for AKI will be
discovered. These new facts will need to be appropriately
incorporated into the RA schema.Table 3 Performance of renal angina within hazard tranches
HT1 HT2 HT3 Entire cohort
Sensitivity (%) 100 92 100 92
Specificity (%) 11 66 76 62
Positive predictive value (%) 17 14 19 16
Negative predictive value (%) 83 86 100 99
Data from Cruz and colleagues [14]. Hazard tranches: HT1, patients at very
high risk; HT2, patients at high risk; HT3, patients at moderate risk.
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